# Debate Matchup Judgment Report

**Gemini 3.8 Flash (high)** vs **MiniMax-M3**

- Paired result: **MiniMax-M3**
- Mean entertainment: `7.50 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Countries should ban the prophylactic use of antibiotics in healthy livestock even if it raises meat prices and reduces yields.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0007__gemini-3.8-flash-high__minimax-m3__s0__tpl_placement_active_20260813a.md): PRO = **Gemini 3.8 Flash (high)**, CON = **MiniMax-M3**
- [Debate B transcript](../../../transcripts/prop_0007__minimax-m3__gemini-3.8-flash-high__s1__tpl_placement_active_20260813a.md): PRO = **MiniMax-M3**, CON = **Gemini 3.8 Flash (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0007__gemini-3.8-flash-high__minimax-m3__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **Gemini 3.8 Flash (high)**, CON = **MiniMax-M3**
- Judged result: Unanimous `3-0` for **MiniMax-M3**.
- Entertainment scores: `7`, `8`, `7`
- Mean signed raw margin (PRO+): `-1.77`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = MiniMax-M3 (CON); B = Gemini 3.8 Flash (high) (PRO) | MiniMax-M3 | -2.0 | -1.94 | 7.0 |
| GPT-5.6 Sol (high) | A = Gemini 3.8 Flash (high) (PRO); B = MiniMax-M3 (CON) | MiniMax-M3 | -1.7 | -1.61 | 8.0 |
| Grok 4.5 (high) | A = MiniMax-M3 (CON); B = Gemini 3.8 Flash (high) (PRO) | MiniMax-M3 | -1.6 | -1.81 | 7.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = MiniMax-M3 (CON); B = Gemini 3.8 Flash (high) (PRO)): CON (A) built the more resilient causal case by distinguishing drug potency/class from raw tonnage, arguing that the pathogens most threatening to human medicine emerge chiefly from therapeutic misuse rather than sub-therapeutic prophylaxis. PRO (B) never squarely rebutted this distinction, mostly reasserting that mass dosing is a large evolutionary proving ground without engaging the potency/class argument. CON also repeatedly pressed that Denmark's success was bundled with massive biosecurity/vaccination investment unavailable to most producers, and that a ban without such substitutes could raise disease incidence and therapeutic antibiotic use—an asymmetry PRO's rebuttal answers ("economic compulsion," "hallmark of confinement not smallholders") addressed only in general, unsupported terms rather than engaging the specific regional/infrastructure point. CON's pressure questions exposed this gap precisely, and its answers to PRO's pressure questions (correctly flagging a strawman on "negligible risk" and reiterating the mechanism distinction) were more directly responsive than PRO's answers, which sidestepped the substitute-capacity question. PRO's case remained rhetorically powerful and emotionally resonant (post-antibiotic catastrophe framing), but it rested on a mechanism CON successfully complicated and an implementation story (Denmark) CON showed was not transferable, leaving PRO's diffuse-benefit claim less secure than CON's concentrated-cost claim.
  Most decisive rebuttal noted: A's Rebuttal 1 point [A2.1]-[A2.2] distinguishing tonnage from resistance-selection potency (chlortetracycline vs. last-line drugs) directly undercut B's central "mass dosing = evolutionary incubator" mechanism, and B never fully closed this gap in later rounds.
- **GPT-5.6 Sol (high)** (A = Gemini 3.8 Flash (high) (PRO); B = MiniMax-M3 (CON)): Side B won by separating the seriousness of AMR from the marginal effectiveness of this particular ban. Side A compellingly explained resistance selection and catastrophic stakes, but repeatedly relied on antibiotic tonnage and the general danger of resistance without adequately answering B's distinctions about drug classes, substitute infrastructure, animal welfare, and smallholder vulnerability. A's claim that economic compulsion would produce affordable husbandry improvements was too asserted to resolve those pressures. B occasionally overstated the idea that the motion required a ban without complementary policy, but still offered the clearer comparative case that benefits were conditional while price, yield, and welfare costs were immediate.
  Most decisive rebuttal noted: Side B's most decisive response was that raw antibiotic tonnage does not establish equivalent human-health risk, followed by the Denmark comparison: reductions occurred alongside vaccination, ventilation, biosecurity, and culling capacity. Side A answered mainly that a ban would compel adaptation, but did not establish that poorer producers could supply those substitutes or prevent a therapeutic rebound.
- **Grok 4.5 (high)** (A = MiniMax-M3 (CON); B = Gemini 3.8 Flash (high) (PRO)): CON (A) won by consistently weakening PRO's causal claim that a prophylaxis ban is a high-leverage AMR fix. CON made the decisive comparative case: certain, concentrated costs (prices, yields, welfare, smallholders) versus diffuse and contested benefits, and repeatedly showed that Denmark/Netherlands gains required bundled biosecurity investment the motion does not supply. PRO had the cleaner high-stakes frame (markets adapt; medicine does not), but left the smallholder/infrastructure and tonnage-vs-risk challenges only partly answered, so the ban-as-solution route never fully closed.
  Most decisive rebuttal noted: CON's Denmark rebuttal: reductions came from paired biosecurity/vaccination/culling capacity, not the ban alone—so PRO's main success case undercuts a freestanding ban.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0007__minimax-m3__gemini-3.8-flash-high__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **MiniMax-M3**, CON = **Gemini 3.8 Flash (high)**
- Judged result: Split `2-1` for **Gemini 3.8 Flash (high)**.
- Entertainment scores: `7`, `8`, `8`
- Mean signed raw margin (PRO+): `-0.27`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Claude Sonnet 5 (high) | A = Gemini 3.8 Flash (high) (CON); B = MiniMax-M3 (PRO) | MiniMax-M3 | +2.2 | +2.14 | 7.0 |
| GPT-5.6 Sol (high) | A = MiniMax-M3 (PRO); B = Gemini 3.8 Flash (high) (CON) | Gemini 3.8 Flash (high) | -1.7 | -1.61 | 8.0 |
| Grok 4.5 (high) | A = Gemini 3.8 Flash (high) (CON); B = MiniMax-M3 (PRO) | Gemini 3.8 Flash (high) | -1.3 | -1.47 | 8.0 |

### Judge Notes

- **Claude Sonnet 5 (high)** (A = Gemini 3.8 Flash (high) (CON); B = MiniMax-M3 (PRO)): PRO (B) built a tighter, more consistent case around the motion's own text ("prophylactic use in healthy livestock"), held that scope line from opening through closing, and repeatedly leveraged the motion's built-in concession on price/yield to reframe the debate as "temporary/recoverable cost vs. irreversible loss of antibiotic efficacy." That asymmetry framing was clear, repeated, and never squarely dismantled. CON (A) landed real points — the perverse-escalation mechanism and the developing-world capital gap were genuine pressure — but CON's central empirical rebuttal (that banning prophylaxis forces higher therapeutic use) was directly contradicted by PRO's EU/Denmark data showing total antimicrobial use, including therapeutic, fell after bans; CON never produced counter-evidence, only plausible assertion and a scope-narrowing move (distinguishing "growth promotion" from "targeted stress-window prophylaxis") that strains against the motion's plain "healthy livestock" language. PRO's answers in the Pressure Questions round were more directly responsive (citing the EU total-usage data, flipping the developing-world harm to AMR's existing toll on children there), while CON's answers largely restated the capital-gap point without new traction. Both sides executed the Q&A format correctly, so no format penalty either way. On balance, PRO's cleaner adherence to the motion's framing, sharper asymmetry argument, and more evidence-grounded rebuttals give it a clear, competitive win.
  Most decisive rebuttal noted: PRO's Rebuttal 2 (A2) directly countering CON's "forces acute therapeutic dosing" claim with the EU total-antimicrobial-use decline data was the most decisive exchange — it neutralized CON's core mechanism argument with the only concrete empirical comparison either side offered, and CON never rebutted it with counter-evidence, only with a capital-gap distinction that shifted rather than resolved the point.
- **GPT-5.6 Sol (high)** (A = MiniMax-M3 (PRO); B = Gemini 3.8 Flash (high) (CON)): Side B won by exposing the gap between banning growth promotion and banning all prophylaxis. Side A established the seriousness of antimicrobial resistance and offered strong irreversibility weighing, but its European evidence concerned growth-promoter restrictions and did not adequately justify prohibiting targeted prevention during predictable high-risk windows. B’s regulated alternative and developing-country comparison therefore remained live, despite some overstated claims about guaranteed outbreaks and yield collapse.
  Most decisive rebuttal noted: Side B’s strongest exchange was its repeated answer to the Denmark example: evidence that antimicrobial use fell after growth-promoter bans does not prove that banning targeted prophylaxis will do the same. Side A never squarely closed that evidentiary and definitional gap.
- **Grok 4.5 (high)** (A = Gemini 3.8 Flash (high) (CON); B = MiniMax-M3 (PRO)): CON (A) won a competitive debate by keeping the decisive clash on instrument and incidence: PRO’s strongest evidence and Denmark/EU story were about growth-promoter phaseouts plus rich-country husbandry, not a blanket ban on targeted prophylaxis in healthy animals during stress windows, and CON repeatedly forced that gap. CON also converted the developing-world burden into a live counter-asymmetry—permanent stunting and protein loss without Danish capital—while offering binding class bans, oversight, and growth-promoter elimination as a tighter alternative. PRO’s irreversible-AMR weighing was memorable and answered pressure well, but never fully closed the definition/evidence stretch or the infrastructure problem the motion itself imposes on “countries.”
  Most decisive rebuttal noted: A’s sustained growth-promoter vs. true-prophylaxis distinction (A2.1–A2.2, A4.1), which stripped PRO’s EU/Denmark results of force for the motion as written and kept the therapeutic-escalation risk live.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0007`
- Side-swap group ID: `prop_0007__gemini-3.8-flash-high__minimax-m3__tpl_placement_active_20260813a`
- Raw paired winner: **MiniMax-M3**
- Mean normalized margin for Gemini 3.8 Flash (high): `-0.74`
- Complete side swap: `yes`
- Included in ratings: `yes`
